-
Biogen Proposes to Acquire Sage Therapeutics for $469M
•
US-based Sage Therapeutics, Inc. (NASDAQ: SAGE) has announced that it received an unsolicited, nonbinding proposal from its partner Biogen Inc. (NASDAQ: BIIB) to acquire all of the outstanding shares of Sage Therapeutics not already owned by Biogen. The proposed acquisition price is USD 7.22 per share. Sage Therapeutics’ Recent PerformanceSage…
-
Biogen and Sage Therapeutics Receive FDA Approval for Postpartum Depression Treatment Zurzuvae
•
Biogen Inc., (NASDAQ: BIIB) and its partner Sage Therapeutics Inc., (NASDAQ: SAGE) have announced that the US Food and Drug Administration (FDA) has granted approval for Zurzuvae (zuranolone), marking it as the world’s first approved therapy for adults with postpartum depression (PPD). The approval is for Zurzuvae’s use as a…
